Pál C, Szili P, Juhász S. Predicting resistance evolution to guide antibiotic development. Nat Rev Microbiol. 2026 Oct 7. doi: 10.1038/s41579-026-01373-0.
Hachani, M.; Gwenzi, T.; Schöttker, B.; Puschhof, J.; Stein-Thöringer, C.; Panagiotou, G.; Brenner, H.; Hoffmeister, M (2026). The Association Between Gut Microbiome and Cachexia in Colorectal Cancer: A Systematic Review. Cancers 2026, 18, 2387. https://doi.org/10.3390/cancers18152387
Vaaben, T. H., Lützhøft, D. O., Hedin, K. A., Ahonen, L., Vazquez-Uribe, R., & Sommer, M. O. A. (2026). Multi-omics analysis of Saccharomyces boulardii supplementation reveals coordinated microbiome, metabolic, and immune signaling changes accompanying tumor suppression. Gut Microbes, 18(1). https://doi.org/10.1080/19490976.2026.2690687
Giannakogeorgou, A., van den Ende, T., Verhaar, B. J. H., de Clercq, N., van Laarhoven, H. W. M., & Nieuwdorp, M#. (2025). Targeting the gut microbiota as a treatment for obesity and cancer cachexia. Expert Opinion on Emerging Drugs, 30(4), 225–240.10.1080/14728214.2026.2650180
Ardis, C.K.#, Bui, T.P.N. & Nieuwdorp, M. Gut microbiota in cancer cachexia: a new frontier for research and therapy. Genes Nutr 20, 28 (2025). 10.1186/s12263-025-00791-8
Roy S, Bahmani AHH, Davids M, Herrema H, Nieuwdorp M# (2025) Modulating the Gut-Muscle Axis: Increasing SCFA-Producing Gut Microbiota Commensals and Decreasing Endotoxin Production to Mitigate Cancer Cachexia. Microorganisms. 10.3390/microorganisms13061356
Fatemeh Safizadeh, MSc; Marko Mandic, MSc; Michael Hoffmeister, PhD; Hermann Brenner# (2025) Colorectal Cancer and Central Obesity. JAMA Network Open. 10.1001/jamanetworkopen.2024.54753
Hedin KA, Mirhakkak MH, Vaaben TH, Sands C, Pedersen M, Baker A, Vazquez-Uribe R, Schäuble S, Panagiotou G#, Wellejus A#, Sommer MOA# (2024) Saccharomyces boulardii enhances anti-inflammatory effectors and AhR activation via metabolic interactions in probiotic communities. ISME Journal. 10.1093/ismejo/wrae212
* indicates shared authorship
# indicates corresponding author